佛慈制药(002644) - 2019 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2019 was ¥156,036,971.07, representing a 9.25% increase compared to ¥142,831,038.91 in the same period last year[9] - Net profit attributable to shareholders decreased by 41.60% to ¥12,977,405.41 from ¥22,222,702.56 year-on-year[9] - The net profit after deducting non-recurring gains and losses fell by 55.00% to ¥9,414,692.59 from ¥20,923,572.76 in the previous year[9] - The total operating revenue for the first quarter of 2019 was CNY 156,036,971.07, an increase of 9.3% compared to CNY 142,831,038.91 in the same period last year[37] - The total operating costs amounted to CNY 144,831,194.22, which is a 22.8% increase from CNY 117,940,698.94 in the previous year[37] - The net profit for the first quarter was CNY 12,977,405.41, down 41.5% from CNY 22,222,702.56 in the same quarter of the previous year[39] - The company's operating revenue for the current period is ¥115,145,123.82, a decrease from ¥122,945,531.34 in the previous period, representing a decline of approximately 6.1%[42] - The net profit for the current period is ¥12,858,126.85, down from ¥21,634,013.36 in the previous period, indicating a decrease of about 40.5%[43] - The total comprehensive income for the current period is ¥12,858,126.85, down from ¥21,634,013.36, showing a decrease of around 40.5%[43] Cash Flow - The net cash flow from operating activities improved by 43.16%, reaching -¥6,319,048.13 compared to -¥11,117,507.95 in the same period last year[9] - Net cash flow from operating activities improved by 43.16% to -¥6,319,048.13, attributed to a decrease in various tax payments compared to the same period last year[18] - The cash flow from operating activities shows a net outflow of ¥6,319,048.13, an improvement from a net outflow of ¥11,117,507.95 in the previous period[47] - Cash and cash equivalents at the end of the period amount to ¥398,400,467.24, down from ¥613,090,487.52 at the end of the previous period, a decrease of approximately 35%[48] - The total cash outflow from investing activities is ¥43,524,025.90, a decrease from ¥100,909,782.77 in the previous period, reflecting a reduction of approximately 57.1%[48] - The net cash flow from operating activities was -11,291,923.24, an improvement from -15,437,057.51 in the previous period, indicating a reduction in cash outflow[51] - Total cash inflow from operating activities was 116,316,873.02, while cash outflow was 127,608,796.26, resulting in a net cash flow of -11,291,923.24[51] - The company reported a cash balance of 390,886,783.05 at the end of the period, down from 607,817,863.77 at the beginning[52] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,459,925,873.02, a decrease of 2.44% from ¥2,521,391,819.51 at the end of the previous year[9] - The company's total assets as of March 31, 2019, were CNY 2,431,083,409.04, a decrease from CNY 2,470,096,123.04 at the end of 2018[36] - The total liabilities decreased to ¥1,005,160,203.52 from ¥1,079,603,555.42, indicating improved financial stability[30] - The total liabilities decreased to CNY 975,327,004.26 from CNY 1,027,197,845.11 at the end of 2018, reflecting a reduction of approximately 5.1%[35] - Total current assets amounted to ¥904,221,292.57, a slight decrease from ¥926,526,714.71 at the end of the previous year[29] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 33,326[12] - The largest shareholder, Gansu Foci Pharmaceutical Industry Development Group Co., Ltd., holds 61.63% of the shares, totaling 314,713,676 shares[12] Expenses - Operating tax and additional fees decreased by 73.23% to ¥400,738.41 due to a reduction in value-added tax payable compared to the same period last year[17] - Management expenses increased by 60.66% to ¥12,340,125.76, primarily due to higher costs associated with production facilities in Lanzhou New Area[17] - The company incurred research and development expenses of ¥3,804,383.56, compared to ¥4,558,756.72 in the previous period, indicating a decrease of about 16.5%[42] - Selling expenses for the current period are ¥11,623,020.03, slightly up from ¥11,515,701.33 in the previous period, showing an increase of approximately 0.9%[42] Other Income and Financial Management - Other income surged by 194.82% to ¥4,039,018.37, mainly from increased government subsidies compared to the previous year[17] - The company terminated a fundraising project and permanently supplemented the remaining funds into working capital, indicating a strategic shift in financial management[20] - The company reported a financial expense of CNY -3,374,342.17, which is an improvement compared to CNY -7,517,579.70 in the previous year[37] - The company reported a financial expense of -¥3,368,524.14, an improvement from -¥7,518,200.03 in the previous period, indicating a reduction in financial costs[42] Inventory and Receivables - Accounts receivable increased by 57.48% to ¥193,139,576.03, attributed to increased sales efforts during the reporting period[16] - Accounts receivable increased to CNY 201,137,726.52 from CNY 165,481,484.14, representing a growth of 21.5%[33] - Inventory levels slightly decreased to CNY 204,146,182.69 from CNY 205,682,549.42, a marginal decline of 0.7%[34]